Dr. Veda Giri discusses registry evaluating genetic testing in prostate cancer
March 1st 2023“The field of germline testing for prostate cancer has expanded significantly; it's really become central in terms of thinking about treatment for men with metastatic prostate cancer,” says Veda Giri, MD.
Dr. Giri and Dr. Loeb discuss prostate cancer genetic testing podcast series
February 22nd 2023“We need to leverage these great platforms to put out high-quality information with experts that people can listen to from home or on the go and get the information that they need,” says Stacy Loeb, MD, MSc.
Sacituzumab govitecan shows efficacy in metastatic urothelial cancer after progression on CPI
February 17th 2023“These data support further evaluation of sacituzumab govitecan—alone or in combination—in patients with metastatic urothelial carcinoma who progressed after prior CPI therapy,” says Daniel P. Petrylak, MD.
Yale professors create new drug that could combat prostate cancer
October 12th 2022A Yale chemist and oncologist collaborated to create a new treatment for prostate cancer that tags specific proteins within the cancerous cells, making it easier for the body’s natural mechanisms to identify and destroy them.
Yale urology chair reflects on first year
September 27th 2022"I have no doubt we’ll become a destination program. We have a great team. Combined with a few key recruitments, we will be set to take our place on the global stage of urology," says Isaac Y. Kim, MD, PhD, MBA, urology professor and chair, Yale Urology.
For Medicaid-insured patients with cancer, health insurance does not always mean health access
July 19th 2022“We found that Medicaid acceptance differed widely across cancer care facilities," said Michael Leapman, MD, MHS, associate professor of Urology, clinical program leader for the Prostate & Urologic Cancers Program at Yale Cancer Center and Smilow Cancer Hospital.
Dr. Petrylak highlights the latest advances in metastatic urothelial cancer
March 22nd 2022In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.